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Abstracts / Biol Blood Marrow Transplant 19 (2013) S211eS232S220medical teams, and emotional effects as most important to
their decision. Results emphasize the importance of ongoing
education for families, the role of the family-physician rela-
tionship, and the value of psychosocial support throughout
the transplant process. Although the current study is limited
by a small convenience sample that may not be representa-
tive of the large sickle cell population (i.e., self-selection to
attend the symposium may indicate greater interest in
pursuing transplant), these ﬁndings provide important
insight into the complexity of family decisions about HSCT.216
Late Pneumocystis Pneumonia After HSCT: Atypical
Presentation and Lack of Correlation with CD4 Count
Taylor Tiffani, Daniele Avila, Steven Z. Pavletic, Daniel Fowler,
Nancy Hardy, David Halverson, Juan Gea-Banacloche.
Experimental Transplantation and Immunology Branch, NCI,
Bethesda, MD
Duration of Pneumocystis pneumonia (PCP) prophylaxis
after allogeneic HSCT is not well deﬁned. Guidelines
recommend at least six months, and longer for patients on
immunosuppression. We report six cases of PCP that
happened late after allo-HSCT (median 36 months, range 19-
80). All had received peripheral blood HSCT: three from
matched sibling donors (MRD), and three from matched
unrelated donors (MUD) (the latter with alemtuzumab
conditioning). At the time of PCP, three patients (#3, #4, #5)
were not on immunosuppression and had no active graft
versus host disease (GVHD). Their mean CD4 T cell count was
569 (range 411-664). The other three had late-acute (#6,
post-DLI) or chronic (#1 and #2) GVHD. Only #1 was on
prednisone (< 0.5 mg/kg); #2 and #6 were on MMF alone.
Their mean CD4 T cell count was 210 (range 86-380). #1 and
#5 were on PCP prophylaxis (dapsone, atovaquone).
Clinical presentationwas atypical. Subacute fever without
shortness of breath (SOB) was most common. Patient #1 was
asymptomatic, with diffuse inﬁltrates found on restaging
chest CT. Only #2 presented with acute SOB and hypoxemia.Tabel 1
Patient #
Age, gender
1
46M
2
35M
3
51M
Disease DLBCL HD DLBCL
Months after
Tx at PCP
36 58 36
HSCT donor MUD (campath) MRD MUD (campa
aGVHD GI No GI, skin
cGVHD Mouth, upper GI,
eyes
Extensive No
GVHD Rx Prednisone,
topical
steroids
MMF, azithromycin,
montelukast
None
CD4 (334-1556) 86 380 411
PCP prophylaxis Dapsone No No
Presentation Asymptomatic Acute SOB cough Subacute fev
CT Diffuse reticular
and ground
glass opacity
Ground glass opacities,
focal consolidation in both
upper lobes, and RML
Diffuse multi
ground glass
reticular opa
in both lungs
BAL GMS+ GMS+ GMS+
DFA+ DFA+ DFA+
PCR+ PCR+ PCR+All patients had ground-glass opacities, but these were pat-
chy/multifocal (n¼4) rather than diffuse (n¼2). PCR was
more sensitive than DFA or GMS. Response to TMP/SMX (Â
steroids) was uniformly positive.
Conclusion: PCP may occur late after transplant, even in the
absence of immunosuppressive therapy, active GVHD or
CD4-T lymphopenia. Patchy ground-glass opacities and
nonspeciﬁc inﬁltrates are the common radiologic feature.
Post-transplant CD4 count does not seem to be useful to
predict PCP or the need for prophylaxis. It is possible that
a qualitative immune T cell defect accounts for late PCP.217
Palliative Care Intergration into an Acute Leukemia and
Bone Marrow Transplant Program
Amy Velasquez 1, Erin Winters 2. 1 BMT, University of Kansas
Hospital, Westwood, KS; 2 BMT, University of Kansas Hospital
Advancements in bonemarrow transplant (BMT) have led
to an increasing number of patients surviving both their
initial cancer diagnosis, and the aggressive treatment used to
cure the cancer. However for most patients, this cure comes
at a signiﬁcant cost. Complications from BMT and chemo-
therapy regimens lead to chronic conditions, which impact
both quality and quantity of life. Palliative care is not only for
dying patients; It provides support for symptom manage-
ment, emotional support, and advance care planning for any
patient and family member facing serious illness. Most
importantly, palliative care improves communication
between the primary physician and family members, and
assists with sometimes very difﬁcult life questions. Clinical
integration of two palliative care MD clinic sessions have
been embedded into the BMT clinic workﬂow in February
2012. The purpose is to measure outcome support for the
staff, patient and family members on an outpatient basis and
increase palliative care physician referrals from the Bone
Marrow Transplant program. In addition, a goal is to increase
patient/family and team planning for end of life care and to
decrease the number of hospital deaths among Bone marrow4
46M
5
55M
6
54M
MZL TCL CLL
19 80 27
th) MUD (campath) MRD MRD
No Skin Skin, liver post-DLI
No No No
None None MMF, topicals
631 664 164
No Atovaquone No
er Subacute fever Subacute fever;
cough
Subacute fever;
cough
focal
and
cities
.
Bilateral ground
glass inﬁltrates.
Multi focal nodular
and diffuse
inﬁltrates.
RLL consolidation and
patchy ground glass
opacities in RML
and LLL.
GMS- GMS- GMS-
DFA- DFA- DFA+
PCR+ PCR+ PCR+
